Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4.06B 601M 522M 488M 447M 843M 57.25B 854M 5.71B 2.24B 28.6B 2.26B 2.21B 95.2B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.92B 728M 632M 592M 541M 1.02B 69.39B 1.04B 6.92B 2.72B 34.67B 2.73B 2.68B 115B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-07 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
30/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
26/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
03/07/25 Realcan Pharmaceutical Vice President Detained MT
03/07/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
03/06/25 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
03/06/25 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day-0.36%
1 week+0.73%
Current month+0.36%
1 month+4.55%
3 months-13.21%
6 months-17.61%
Current year-14.29%
1 week 2.7
Extreme 2.7
2.83
1 month 2.51
Extreme 2.51
2.89
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 26/04/2021
President 61 26/05/2023
Corporate Officer/Principal 40 30/10/2019
Director TitleAgeSince
Chairman 61 21/11/2009
Director/Board Member 43 21/11/2009
Chairman 48 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+0.73%-12.66%-23.33% 603M
-1.54%-0.14%+22.81%+104.69% 103B
-0.31%+4.85%+52.03%+158.17% 56.03B
+0.34%+0.34%+3.82%+283.33% 24.18B
-0.18%-1.02%-14.56%-17.77% 8.2B
-0.36%-4.89%-38.67%-32.59% 7.25B
-0.93%-3.39%-9.48%-30.49% 6.87B
+0.05%-1.10%+21.05%+18.63% 6.17B
-1.06%-4.34%-2.39%+21.64% 5.22B
+0.81%-3.32%-8.50%-7.65% 3.63B
Average -0.39%-1.56%+1.35%+47.46% 22.09B
Weighted average by Cap. -0.82%+0.00%+22.48%+118.00%

Financials

2024 2025
Net sales 7.97B 1.18B 1.02B 959M 877M 1.66B 112B 1.68B 11.22B 4.4B 56.16B 4.43B 4.33B 187B 7.3B 1.08B 938M 878M 803M 1.52B 103B 1.54B 10.27B 4.03B 51.43B 4.06B 3.97B 171B
Net income 20.62M 3.05M 2.65M 2.48M 2.27M 4.29M 291M 4.34M 29.04M 11.4M 145M 11.47M 11.22M 484M 16.07M 2.38M 2.07M 1.93M 1.77M 3.34M 227M 3.38M 22.63M 8.88M 113M 8.94M 8.74M 377M
Net Debt 1.6B 236M 205M 192M 176M 332M 22.51B 336M 2.25B 882M 11.25B 887M 868M 37.43B 860M 127M 111M 104M 94.72M 179M 12.14B 181M 1.21B 475M 6.06B 478M 468M 20.19B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
06/08/26 CN¥2.760 -0.36% 25,912,860
05/08/26 CN¥2.770 -0.72% 26,396,100
04/08/26 CN¥2.790 +0.36% 19,728,841
03/08/26 CN¥2.780 +1.09% 20,863,544
31/07/26 CN¥2.750 +1.48% 24,248,217
  1. Stock Market
  2. Stocks
  3. 002589 Stock